title: Biochemical and ultrastructural studies suggest that the effects of thapsigargin on human platelets are mediated by changes in intracellular calcium but not by intracellular histamine.
abstract: The involvement of intracellular histamine in thapsigargin (Tg)-induced platelet aggregation was studied. Platelet aggregation induced by 0.25 and 0.5 microM Tg was not accompanied by a rise in intracellular histamine but a significant (p < 0.01) increase in the level of intracellular histamine was observed at 1 microM Tg. Preincubation of platelets with inhibitors of histamine metabolizing enzymes had little effect on intracellular histamine levels in platelets stimulated by 0.5 microM Tg. In addition, the inhibitors of histidine decarboxylase (HDC), alpha-methyl histidine (alpha-MH) and alpha-fluoromethyl histidine (alpha-FMH) failed to inhibit Tg-induced aggregation. The intracellular histamine receptor antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl (DPPE), inhibited Tg-induced aggregation but with IC50 values dependent on the concentration of agonist used. The inhibitory effects of DPPE on Tg-induced aggregation were not reversed by the addition of histamine to saponin-permeabilized platelets suggesting non-histamine mediated effects of DPPE on Tg-induced aggregation. Tg stimulated an increase in the cytosolic free calcium concentration which was unaffected by DPPE indicating that the effects of DPPE are also not due to the inhibition of mobilization of cytosolic calcium. The ultrastructural studies suggest that the major Tg-induced changes (pseudopod formation and granule centralization) are consistent with a primary role for Tg to mobilize calcium; DPPE had very little effect on these ultrastructural changes. The results indicate that the effects of Tg on human platelets are mediated by an increase in cytosolic calcium but not by intracellular histamine.
authors.affiliation: Manitoba Institute of Cell Biology, Winnipeg, Canada.
authors.forename: S P
authors.initials: SP
authors.lastname: Saxena
authors.forename: A
authors.initials: A
authors.lastname: McNicol
authors.forename: A B
authors.initials: AB
authors.lastname: Becker
authors.forename: L J
authors.initials: LJ
authors.lastname: Brandes
authors.forename: O
authors.initials: O
authors.lastname: Thastrup
authors.forename: J M
authors.initials: JM
authors.lastname: Gerrard
mesh_terms: D001792:Blood Platelets / Q000187:drug effects* / Q000648:ultrastructure; D002118:Calcium / Q000097:blood*; D005260:Female; D006632:Histamine / Q000097:blood*; D006633:Histamine Antagonists; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D010714:Phosphatidylethanolamines / Q000494:pharmacology; D010936:Plant Extracts / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D013729:Terpenes / Q000494:pharmacology*; D019284:Thapsigargin
chemical_list: D006633:Histamine Antagonists; D010714:Phosphatidylethanolamines; D010936:Plant Extracts; D010975:Platelet Aggregation Inhibitors; D013729:Terpenes; C007510:1,2-dipalmitoyl-3-phosphatidylethanolamine; D019284:Thapsigargin; D006632:Histamine; D002118:Calcium